Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review

Keyphrases

• Once-daily 100%
• Clinical Benefit 100%
• Chronic Obstructive Pulmonary Disease 100%
• Indacaterol 100%
• Glycopyrronium 100%
• Dual Bronchodilation 100%
• Fixed Dose 100%
• Indacaterol/glycopyrronium 85%
• Long-acting Bronchodilators 42%
• Clinically Significant 28%
• Inhaled Corticosteroids 28%
• Tiotropium 28%
• No Significant Difference 14%
• Therapeutic Potential 14%
• Randomized Controlled Trial 14%
• Placebo 14%
• Twice Daily 14%
• Clinical Efficacy 14%
• Health Status 14%
• Nave 14%
• Disease Outcome 14%
• Very Severe 14%
• Lung Function 14%
• Fixed Combination 14%
• Maintenance Therapy 14%
• Long-acting β2-agonist 14%
• Fluticasone Propionate 14%
• Severe Chronic Obstructive Pulmonary Disease 14%
• Global Initiative for Chronic Obstructive Lung Disease 14%
• Dyspnea Score 14%
• Exercise Endurance 14%
• Glycopyrronium Bromide 14%
• Moderate Exacerbations 14%
• Endurance Time 14%
• Single Therapy 14%
• Severe Exacerbation 14%
• Well Tolerated 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Glycopyrronium 100%
• Chronic Obstructive Lung Disease 100%
• Indacaterol 100%
• Bronchodilating Agent 50%
• Corticosteroid 25%
• Placebo 12%
• Randomized Controlled Trial 12%
• Health Status 12%
• Clinical Study 12%
• Dyspnea 12%
• Salmeterol 12%
• Fluticasone 12%